Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials

RTS,S/AS01 (GSK) is the world’s first malaria vaccine. However, despite initial efficacy of almost 70% over the first 6 months of follow-up, efficacy waned over time. A deeper understanding of the immune features that contribute to RTS,S/AS01-mediated protection could be beneficial for further vaccine development. In two recent controlled human malaria infection (CHMI) trials of the RTS,S/AS01 vaccine in malaria-naïve adults, MAL068 and MAL071, vaccine efficacy against patent parasitemia ranged from 44% to 87% across studies and arms (each study included a standard RTS,S/AS01 arm with three vaccine doses delivered in four-week-intervals, as well as an alternative arm with a modified version of this regimen). In each trial, RTS,S/AS01 immunogenicity was interrogated using a broad range of immunological assays, assessing cellular and humoral immune parameters as well as gene expression. Here, we used a predictive modeling framework to identify immune biomarkers measured at day-of-challenge that could predict sterile protection against malaria infection. Using cross-validation on MAL068 data (either the standard RTS,S/AS01 arm alone, or across both the standard RTS,S/AS01 arm and the alternative arm), top-performing univariate models identified variables related to Fc effector functions and titer of antibodies that bind to the central repeat region (NANP6) of CSP as the most predictive variables; all NANP6-related variables consistently associated with protection. In cross-study prediction analyses of MAL071 outcomes (the standard RTS,S/AS01 arm), top-performing univariate models again identified variables related to Fc effector functions of NANP6-targeting antibodies as highly predictive. We found little benefit–with this dataset–in terms of improved prediction accuracy in bivariate models vs. univariate models. These findings await validation in children living in malaria-endemic regions, and in vaccinees administered a fourth RTS,S/AS01 dose. Our findings support a “quality as well as quantity” hypothesis for RTS,S/AS01-elicited antibodies against NANP6, implying that malaria vaccine clinical trials should assess both titer and Fc effector functions of anti-NANP6 antibodies.

[1]  Rachel L. Spreng,et al.  Magnitude, Specificity, and Avidity of Sporozoite-Specific Antibodies Associate With Protection Status and Distinguish Among RTS,S/AS01 Dose Regimens , 2020, Open Forum Infectious Diseases.

[2]  E. Soderblom,et al.  Genetic disruption of WASHC4 drives endo-lysosomal dysfunction and cognitive-movement impairments in mice and humans , 2020, bioRxiv.

[3]  D. Lauffenburger,et al.  Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination , 2020, Science Translational Medicine.

[4]  E. Bergmann-Leitner,et al.  Role of Opsonophagocytosis in Immune Protection against Malaria , 2020, Vaccines.

[5]  R. A. van den Berg,et al.  The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection , 2020, Frontiers in Immunology.

[6]  S. Chaudhury,et al.  A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses , 2020, eLife.

[7]  M. Laurens.  RTS,S/AS01 vaccine (Mosquirix™): an overview , 2019, Human vaccines & immunotherapeutics.

[8]  A. Vejux,et al.  Peroxisomes in Immune Response and Inflammation , 2019, International journal of molecular sciences.

[9]  Kwaku Poku Asante,et al.  Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy , 2019, Nature Communications.

[10]  Peter J. Hogarth,et al.  The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease , 2019, Front. Immunol..

[11]  K. Wilson,et al.  Malaria vaccines in the eradication era: current status and future perspectives , 2019, Expert review of vaccines.

[12]  Oliver M. Crook,et al.  Combining LOPIT with differential ultracentrifugation for high-resolution spatial proteomics , 2019, Nature Communications.

[13]  Kwaku Poku Asante,et al.  Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children , 2018, BMC Medicine.

[14]  M. Rosenkilde,et al.  EBI2 in splenic and local immune responses and in autoimmunity , 2018, Journal of leukocyte biology.

[15]  S. Alam,et al.  Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens , 2018, The Journal of Immunology.

[16]  H. Saeki.  Faculty of 1000 evaluation for Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. , 2018 .

[17]  T. K. van den Berg,et al.  Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody‐dependent cellular cytotoxicity towards cancer cells , 2018, European journal of immunology.

[18]  J. McCarthy,et al.  Controlled Human Malaria Infection: Applications, Advances, and Challenges , 2017, Infection and Immunity.

[19]  A. Wallqvist,et al.  Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis , 2017, Scientific Reports.

[20]  J. Cyster,et al.  Distinct oxysterol requirements for positioning naïve and activated dendritic cells in the spleen , 2017, Science Immunology.

[21]  Eva K. Lee,et al.  Systems analysis of protective immune responses to RTS,S malaria vaccination in humans , 2017, Proceedings of the National Academy of Sciences.

[22]  E. Jongert,et al.  A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum , 2016, Malaria Journal.

[23]  Paige E. Waterman,et al.  Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. , 2016, The Journal of infectious diseases.

[24]  A. Wallqvist,et al.  The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity , 2016, Malaria Journal.

[25]  J. Cyster,et al.  EBI2 augments Tfh cell fate by promoting interaction with IL2-quenching dendritic cells , 2016, Nature.

[26]  Karen G. Dowell,et al.  Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control , 2016, PLoS pathogens.

[27]  Pablo Tamayo,et al.  Compendium of Immune Signatures Identifies Conserved and Species-Specific Biology in Response to Inflammation. , 2016, Immunity.

[28]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[29]  Kwaku Poku Asante,et al.  Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial , 2015 .

[30]  S. Hoffman,et al.  The march toward malaria vaccines. , 2015, Vaccine.

[31]  N. Hawkes.  European Medicines Agency approves first malaria vaccine , 2015, BMJ : British Medical Journal.

[32]  S. C. T. P. Rts.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial , 2015, The Lancet.

[33]  W. Ballou,et al.  Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults , 2015, PloS one.

[34]  Michael D. Porter,et al.  IgG2 Antibodies against a Clinical Grade Plasmodium falciparum CSP Vaccine Antigen Associate with Protection against Transgenic Sporozoite Challenge in Mice , 2014, PloS one.

[35]  B. Greenwood,et al.  Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites , 2014, PLoS medicine.

[36]  S. Lohse,et al.  Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity , 2014, mAbs.

[37]  Sandra Romero-Steiner,et al.  Molecular signatures of antibody responses derived from a systems biological study of 5 human vaccines , 2013, Nature Immunology.

[38]  R. Brink,et al.  B cell localization: regulation by EBI2 and its oxysterol ligand. , 2013, Trends in immunology.

[39]  W. Blattner,et al.  HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life , 2013, Mucosal Immunology.

[40]  Kwaku Poku Asante,et al.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. , 2012, The New England journal of medicine.

[41]  T. Mayadas,et al.  Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo. , 2012, Blood.

[42]  John N. Nkengasong,et al.  Detection of Recent HIV-1 Infection Using a New Limiting-Antigen Avidity Assay: Potential for HIV-1 Incidence Estimates and Avidity Maturation Studies , 2012, PloS one.

[43]  Pedro Alonso,et al.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. , 2011, The New England journal of medicine.

[44]  B. Haynes,et al.  Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection , 2011, AIDS.

[45]  N. Hacohen,et al.  Peroxisomes Are Signaling Platforms for Antiviral Innate Immunity , 2010, Cell.

[46]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[47]  V. A. Stewart,et al.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.

[48]  Vicki C. Ashley,et al.  Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.

[49]  Virginia Pascual,et al.  A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. , 2008, Immunity.

[50]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.

[51]  K. Kester,et al.  Opsonization by antigen‐specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein‐based vaccine , 2003, Parasite immunology.

[52]  W. Fridman,et al.  FcγRII expression in resting and activated B lymphocytes , 1989 .

[53]  J. Stockman.  First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children , 2013 .

[54]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.